Welcome to our dedicated page for ACTUATE THERAPEUTICS SEC filings (Ticker: ACTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Actuate Therapeutics, Inc. filings document a clinical-stage oncology issuer with Nasdaq-listed common stock and emerging growth company status. Registration statements and capital-structure disclosures cover the company's common stock offering, security terms, and public-company reporting framework.
Actuate's 8-K and proxy filings record material events, Regulation FD clinical disclosures for elraglusib in metastatic pancreatic ductal adenocarcinoma, material agreements, shareholder voting matters, board composition, director elections, auditor ratification, governance matters, and risk-related disclosures tied to its biopharmaceutical development program.
Actuate Therapeutics, Inc. reported equity compensation activity for President, CEO and Director Daniel M. Schmitt on August 14, 2026. A block of 272,056 restricted stock units vested and settled into the same number of common shares, consistent with prior grants. To cover federal and state tax withholding on this settlement, 120,521 shares of common stock were withheld by the company at a per-share value of $1.01. Following these transactions, Schmitt is also shown as trustee for several irrevocable family trusts, including one holding 564,071 common shares and others each holding 22,223 shares, which are reported as indirect ownership.
Actuate Therapeutics reported a net loss of $4.9 million for the quarter and $10.5 million for the six months ended June 30 2026, narrowing losses versus 2025 as research and development and general and administrative expenses both declined.
Cash and cash equivalents were $4.4 million with working capital of $0.94 million, and management estimates existing cash will not fund operations beyond September 2026 without additional capital, leading to a stated substantial doubt about continuing as a going concern. The company has an unused capacity of about $98.7 million under its at-the-market equity facility and a separate Committed Equity Facility.
Operationally, Actuate advanced its lead GSK‑3β inhibitor elraglusib. An oral tablet IND was cleared by the FDA for a Phase 1/2 study in advanced cancers, following Phase 2 IV results in first-line metastatic pancreatic cancer that showed improved median overall survival and higher 12‑ and 24‑month survival rates versus control. The company also agreed to evaluate elraglusib in the BEACON2 pediatric neuroblastoma platform study.
Actuate Therapeutics, Inc. disclosed that Nasdaq’s listing qualifications staff notified it that from June 1, 2026 to July 14, 2026 its Market Value of Listed Securities (MVLS) was below the $50 million minimum required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A). The notice has no immediate effect, and the common stock continues to trade under the symbol ACTU.
Under Nasdaq Listing Rule 5810(c)(3)(C), Actuate has 180 calendar days from the July 15, 2026 notice, through January 11, 2027, to regain compliance by having MVLS close at $50 million or more for at least ten consecutive business days. If it does not regain compliance, Nasdaq may initiate delisting, which the company could appeal, or it may consider transferring to the Nasdaq Capital Market. Actuate states it will actively monitor MVLS and take reasonable measures to meet the MVLS requirement, while noting there is no assurance it will regain or maintain compliance.
Actuate Therapeutics, Inc. held its virtual Annual Meeting of Stockholders on May 21, 2026. Stockholders elected two Class II directors, Aaron G.L. Fletcher, Ph.D. and Jason Keyes, each to serve three-year terms ending at the 2029 Annual Meeting, continuing until their successors are elected and qualified.
Fletcher received 14,877,247 votes for and 1,883,025 withheld, with 1,871,309 broker non-votes. Keyes received 16,727,875 votes for and 32,397 withheld, with 1,871,309 broker non-votes. Stockholders also ratified Crowe LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 18,571,817 votes for, 50,023 against, and 9,741 abstentions.
ACTUATE THERAPEUTICS, INC. director Dan Zabrowski received a grant of stock options as part of his compensation. The grant covers 15,000 options for Common Stock at an exercise price of $2.42 per share. These options were granted on May 21, 2026 and will vest in full on the one-year anniversary of the grant date. After this award, he holds 15,000 derivative securities directly, with the options scheduled to expire on May 21, 2036.
ACTUATE THERAPEUTICS, INC. director and 10% owner Todd S. Thomson received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share, vest in full on the one-year anniversary of the grant date, and expire on May 21, 2036. Certain funds managed by Kairos Venture Investments, LLC are entitled to an indirect economic interest in these options because Thomson serves on the board as their representative.
ACTUATE THERAPEUTICS, INC. director Roger Sawhney received a grant of stock options that give him the right to buy 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036.
All 15,000 options relate to common stock and were acquired as a compensation grant, not through an open-market purchase. According to the footnote, these options will vest in full on the first anniversary of the grant date, so they become exercisable after that time.
Actuate Therapeutics director Amy L. Ronneberg received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.42 per share and expire on May 21, 2036. According to the footnote, these options vest in full on the first anniversary of the grant date. Following this award, her reported derivative holdings from this grant total 15,000 options.
ACTUATE THERAPEUTICS, INC. director Jason A. Keyes received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036. According to the footnote, the options will vest in full on the first anniversary of the grant date, meaning Keyes must remain eligible through that date before the award is fully exercisable. Following this grant, his reported derivative holdings from this award total 15,000 stock options.
ACTUATE THERAPEUTICS, INC. director Martin H. Huber Jr. received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036. According to the filing, these options will vest in full on the anniversary of the grant date. Following this award, the filing shows Huber holding 15,000 stock options directly.